Ogadimma Arisukwu | cancer | Editorial Board Member

Published on by Oncology

Dr. Ogadimma Arisukwu | cancer | Editorial Board Member

Research Scholar | Landmark University | Nigeria

Dr. Ogadimma Arisukwu is an accomplished social scientist and lecturer at Landmark University, Omu-Aran, Nigeria, whose scholarship spans social policy, public health systems, community studies, and socio-cultural dynamics within African societies. His research examines the intersection of governance, health service delivery, livelihood realities, and culturally rooted behavioral responses, with a particular focus on how institutional structures shape societal well-being. Dr. Arisukwu’s work offers evidence-based insights into contemporary sociological challenges, including health insurance utilization, socio-cultural perceptions of reproductive technologies, and emerging threats such as employment scams that affect vulnerable populations. His publications demonstrate strong methodological rigor, integrating qualitative and quantitative approaches to understand lived experiences, inform policy reforms, and strengthen community resilience. As an active academic contributor, he has authored numerous peer-reviewed studies in reputable international journals, contributing to global debates on health equity, social justice, and cultural determinants of human behavior. Dr. Arisukwu engages in interdisciplinary collaborations with scholars across Nigeria and beyond, promoting research that bridges academic inquiry and practical societal needs. His work carries substantial societal relevance, supporting better-informed policymaking, advancing inclusive healthcare practices, and deepening understanding of cultural frameworks that shape public perception and behavior. Through sustained research productivity and community-centered academic engagement, he has established himself as a respected voice in sociology and social policy research. Dr. Arisukwu’s academic influence and research productivity are reflected in his metrics 212 citations, 31 documents, and an h-index of 9.

Profiles: Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Job scams in Ibadan (2024) Arisukwu, O., et al. (2024). Job advertisements and lived experiences of victims of job scams in Ibadan, Nigeria. International Journal of Sociology and Social Policy.
(Citations: 2)

2. NHIS–HMO healthcare perception (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Healthcare service delivery perception among NHIS-HMO enrollees in Lagos hospitals. Humanities and Social Sciences Communications. (Citations: 2)

3. Religious & cultural interpretations of artificial insemination (2023) Authors include: Arisukwu, O., et al. (2023). Religious and cultural interpretations of artificial insemination in South-West Nigeria. AJOG Global Reports. (Citations: 4)

4. Attitudes of medical personnel in Lagos hospitals (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Perception among NHIS–HMO enrolees of the attitudes of medical personnel during outpatient care in Lagos hospitals. International Journal of Environmental Research and Public Health, 20(2). https://doi.org/10.3390/ijerph20021218

5. Youth gambling in Nigeria (2021)

Adebisi, T., Alabi, O., Arisukwu, O., & Asamu, F. (2021). Gambling in transition: Assessing youth narratives of gambling in Nigeria. Journal of Gambling Studies. https://doi.org/10.1007/s10899-020-09982-x

Hifzur R Siddique | Cancer Science | Editorial Board Member

Published on by Oncology

Assist. Prof. Dr. Hifzur R Siddique | Cancer Science | Editorial Board Member

Assistant Professor | Aligarh Muslim University | India

Dr. Hifzur R. Siddique is a distinguished researcher and academic at Aligarh Muslim University, India, specializing in cancer biology, nanomedicine, stem cell research, chemoresistance mechanisms, and translational therapeutics. His work spans the synthesis and characterization of metal oxide nanoparticles with anticancer potential, epigenetic regulation in cancer, and preclinical evaluation of natural compounds like lupeol for chemotherapeutic applications. Dr. Siddique has contributed significantly to methodological advancements, including the use of Drosophila melanogaster models for DNA damage studies and luciferase-based reporter assays for kinase activity assessment. With a robust portfolio of 103 publications in high-impact journals, book chapters, and systematic reviews, he collaborates extensively with over 340 co-authors worldwide, reflecting his leadership in multidisciplinary cancer research. His studies not only advance fundamental understanding of tumor biology but also address translational challenges, bridging laboratory findings to clinical and societal impact. Dr. Siddique’s research has influenced global guidelines on rare malignancies such as NUT carcinoma and contributed to the development of nanocomposite-based therapeutic strategies. His work embodies a commitment to improving cancer outcomes, fostering innovation, and mentoring the next generation of scientists in oncology and biomedical sciences. Dr. Siddique’s academic influence and research productivity are reflected in his metrics 3,083 citations, 103 documents, and an h-index of 30.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

Siddique, H. R., & Saleem, M. (2011). Beneficial health effects of lupeol triterpene: A review of preclinical studies. Life Sciences, 88(7-8), 285–293. [Cited by 477]

Siddique, H. R., & Saleem, M. (2012). Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences. Stem Cells, 30(3), 372–378. [Cited by 419]

Mishra, S. K., Siddique, H. R., & Saleem, M. (2012). S100A4 calcium-binding protein is key player in tumor progression and metastasis: Preclinical and clinical evidence. Cancer and Metastasis Reviews, 31(1), 163–172. [Cited by 212]

Siddique, H. R., Chowdhuri, D. K., Saxena, D. K., & Dhawan, A. (2005). Validation of Drosophila melanogaster as an in vivo model for genotoxicity assessment using modified alkaline Comet assay. Mutagenesis, 20(4), 285–290. [Cited by 146]

Fatma, H., Maurya, S. K., & Siddique, H. R. (2022). Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance. Seminars in Cancer Biology, 83, 166–176. [Cited by 136]

Jun Lu | Cancer | Editorial Board Member

Published on by Oncology

Prof. Jun Lu | Cancer | Editorial Board Member

Professor | Chengdu University of Traditional Chinese Medicine | China

Dr. Jun Lu is a distinguished researcher at Chengdu University of Traditional Chinese Medicine, China, specializing in cancer nanomedicine, biomaterials, and translational therapeutics. His work focuses on the design and development of multifunctional nanoplatforms, including engineered chitosan nanoparticles, aptamer-conjugated chemotherapeutics, and self-gelling biomaterials for applications in tumor therapy, wound healing, and infectious disease management. Dr. Lu integrates molecular biology, materials science, and bioengineering to advance innovative therapeutic strategies, such as modulating tumor microenvironments, orchestrating DNA damage pathways in colorectal carcinoma, and promoting MRSA-infected wound healing. He has authored 78 publications in high-impact journals including Journal of Translational Medicine, Chemical Engineering Journal, Carbohydrate Polymers, and Nano Research, reflecting strong expertise in nanobiotechnology and translational oncology. His extensive collaborations with over 380 co-authors worldwide demonstrate his leadership in multidisciplinary research networks, bridging fundamental science with clinical applications. Beyond academic contributions, Dr. Lu’s work has significant societal impact by enabling advanced therapies for cancer, infectious diseases, and tissue repair, providing novel solutions to global health challenges. His research emphasizes translational relevance and real-world applicability, contributing to safer, more effective, and innovative therapeutic modalities. Dr. Lu’s academic influence and research productivity are reflected in his metrics 2,421 citations, 78 documents, and an h-index of 24.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

Lu, J., Zhang, H., Hou, J., Li, X., Hu, X., Hu, Y., Easton, C. D., Li, Q., Sun, C., … (2020). Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks. Nature Materials, 19(7), 767–774. Cited by: 495

Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., Zhang, G. (2017). Chemical modifications of nucleic acid aptamers for therapeutic purposes. International Journal of Molecular Sciences, 18(8), 1683. Cited by: 384

Lu, J., Jiang, F., Lu, A., Zhang, G. (2016). Linkers having a crucial role in antibody–drug conjugates. International Journal of Molecular Sciences, 17(4), 561. Cited by: 352

Tan, C. M., Therien, A. G., Lu, J., Lee, S. H., Caron, A., Gill, C. J., Lebeau-Jacob, C., … (2012). Restoring Methicillin-Resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Science Translational Medicine, 4(126), 126ra35.
Cited by: 328

Li, F., Lu, J., Liu, J., Liang, C., Wang, M., Wang, L., Li, D., Yao, H., Zhang, Q., Wen, J., … (2017). A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications, 8(1), 1390.
Cited by: 275

 

Ramon Mangues | Cancer | Best Research Article Award

Published on by Oncology

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301

Dr. YuBing Luo | Computational Biology | Best Researcher Award

Published on by Oncology

Dr. YuBing Luo | Computational Biology | Best Researcher Award

North China University of Technology | China

Author Profile

Scopus

🎓 Academic Background

Ph.D. in Engineering

  • Institution: North University of China
  • Program: Direct-Ph.D. Program (2nd Year)

🔬 Research Experience

Research Focus:

  • Medical image segmentation and processing
  • Deep learning for histology image analysis

🏆 Honors & Awards

Academic Scholarships:

  • 2023-2024: First-Class Academic Scholarship
  • 2022-2023: Special Academic Scholarship
  • 2021-2022: First-Class Comprehensive Scholarship
  • 2021-2022: Special Academic Scholarship

Other Awards:

  • 2022-2023: Excellent Youth League Member, School Level
  • 2021-2022: Three-Good Student, North University of China

💻 Technical Skills

Programming Languages: Python, MATLAB
Deep Learning Frameworks: TensorFlow, PyTorch
Tools: OpenCV, Scikit-Learn, Keras

🌟 Self-Evaluation

Proactive and skilled in public relations, with strong communication abilities and experience in event planning and organization. Highly responsible, hardworking, and adaptive to changes and challenges. Possesses excellent learning capabilities with a strategic approach to skill development and continuous improvement.

✨Conclusion:

  • In summary, this individual is a dedicated Ph.D. candidate at North University of China, specializing in advanced medical image segmentation and deep learning for histology analysis. With a solid record of academic scholarships and accolades, they demonstrate exceptional technical skills in Python, MATLAB, and deep learning frameworks. Their commitment to learning, strong organizational abilities, and adaptable, challenge-ready mindset make them a valuable asset in the fields of biomedical engineering and deep learning.

📊🔬NOTABLE PUBLICATION:
  • Title: Boundary Fusion Multi-Scale Enhanced Network for Gland Segmentation in Colon Histology Images
    • Authors: Luo, Y., Qin, P., Chai, R., Zhai, S., Yan, J.
    • Journal: Biomedical Signal Processing and Control
    • Year: 2024

 

  • Title: FFS-Net: Fourier-Based Segmentation of Colon Cancer Glands Using Frequency and Spatial Edge Interaction
    • Authors: Luo, Y.B., Cai, J.H., Qin, P.L., Zhai, S.J., Qin, J.
    • Journal: Expert Systems with Applications
    • Year: 2025

Assoc Prof Dr. Haruto Nishida | Breast Cancer Immunity | Best Researcher Award

Published on by Oncology

Assoc Prof Dr. Haruto Nishida | Breast Cancer Immunity | Best Researcher Award

Faculty of Medicine, Oita University | Japan

Author Profile

Scopus

🧬 Dr. Haruto Nishida, M.D., Ph.D. – Associate Professor of Diagnostic Pathology

Haruto Nishida, M.D., Ph.D., is an Associate Professor at the Department of Diagnostic Pathology at Oita University Hospital, Japan, where he has served in this role since April 2021. Dr. Nishida has a profound expertise in pathology, with a particular focus on diagnostic pathology, cytology, and molecular pathology.

🎓 Education and Early Career

Dr. Nishida earned his Medical Degree from the Faculty of Medicine at Oita University in 2009. He furthered his academic journey by obtaining a Ph.D. from the same institution in 2015, specializing in pathology. His post-graduate training includes a residency in General Medicine at Oita Medical Hospital and a fellowship in Diagnostic Pathology at Oita University.

🩺 Professional Experience

Dr. Nishida’s career at Oita University has been marked by progressive roles. Starting as an Assistant Professor in 2012, he was promoted to Lecturer in 2019 and then to Associate Professor in 2020. He continued in this role when he transitioned to Oita University Hospital in 2021, where he currently leads efforts in diagnostic pathology.

🏅 Board Certifications and Licensure

Dr. Nishida holds multiple prestigious board certifications, including the Japanese Board Certification in Pathology, Autopsy, Cytology, and Molecular Pathology. He earned his National Board of Medicine license in 2009, showcasing his dedication to the field.

🌍 Professional Affiliations

Dr. Nishida is an active member of several professional organizations, both in Japan and internationally. He is involved with the Japanese Society of Pathology, Japanese Society of Clinical Cytology, Japan Dermatopathology Society, and the Bone and Soft Tissue Tumor Club of Japan. Additionally, he is a member of the United States and Canadian Academy of Pathology (USCAP) and the International Academy of Cytology.

Dr. Nishida’s contributions to the field of pathology, combined with his ongoing research and teaching, make him a distinguished figure in diagnostic pathology.

🚀 Conclusion

In summary, Dr. Haruto Nishida is a highly accomplished pathologist whose extensive expertise and dedication to diagnostic pathology have significantly contributed to the field. His career, marked by a progression of academic and clinical roles at Oita University, is underpinned by his strong educational background and numerous board certifications. As an active member of both national and international professional organizations, Dr. Nishida continues to impact the field through his research, teaching, and clinical work. His ongoing commitment to excellence in pathology makes him a respected leader in the medical community.

 

📊🔬NOTABLE PUBLICATION:

 

  • SOX10-Internal Tandem Duplications and PLAG1 or HMGA2 Fusions Segregate Eccrine-Type and Apocrine-Type Cutaneous Mixed Tumors
    Authors: Macagno, N., Kervarrec, T., Thanguturi, S., De la Fouchardière, A., Battistella, M.
    Journal: Modern Pathology
    Year: 2024

 

  • Recurrent Cardiac Tamponade Following Coronavirus Disease 2019 mRNA Vaccination: A Case Report
    Authors: Kaimori, R., Nishida, H., Yahiro, T., Iwami, T., Daa, T.
  • Journal: Cardiovascular Pathology
    Year: 2024

 

  • Lipid Droplet Detection in Histopathological Images Using Reinforcement Learning
    Authors: Harada, Y., Nishida, H., Matsuura, K.
    Journal: Biotechnology and Biotechnological Equipment
    Year: 2024

 

  • Right Atrial Cardiac Myxoma with Malignant Transformation to Undifferentiated Sarcoma: A Case Report
    Authors: Kaimori, R., Nishida, H., Oyama, Y., Kawamura, K., Daa, T.
    Journal: Cardiovascular Pathology
    Year: 2024

 

  • The Relationship Between Tumor Immunity and the cGAS–STING Pathway in Breast Cancer: An Immunohistochemical Study
    Authors: Nishida, H., Ohara, N., Kato, A., Kawamura, K., Daa, T.
    Journal: Experimental and Molecular Pathology
    Year: 2024

Dr. Abdulhadi Aljawish | Cytotoxicity | Best Researcher Award

Published on by Oncology

Dr. Abdulhadi Aljawish | Cytotoxicity | Best Researcher Award

National Conservatory of Arts and Crafts | France

Author Profile

Scopus

Google Scholar

Biography: Dr. Abdulhadi ALJAWISH

🧑‍🔬 Education

2009-2013: Ph.D. in Biotechnological and Food Processes (with Honors)
Laboratoire d’Ingénierie des Biomolécules-ENSAIA, Université de Lorraine, Nancy, France
Thesis: “Enzymatic functionalization of chitosan with phenolic compounds by Myceliophthora thermophila laccase”
Advisors: Prof. Joël SCHER, Prof. Isabelle CHEVALOT
Defense Date: 08/07/2013

2008-2009: Master’s in Biotechnology, Agro-resources, Food, Nutrition (B.A.A.N) (with Merit)
Laboratoire de Biocatalyse-Bioprocédés (LBB), ENSAIA-INPL, Nancy, France
Research: “Enzymatic synthesis of natural colorants from phenolic compounds”
Advisors: Prof. Michel GIRARDIN, Dr. Lionel MUNIGLIA

👨‍💼 Professional Experience

2021-2023: Head of Research & Development in Enzymatic Processes
SAS GECCO, Institut Charles VIOLLETTE – Laboratoire des Procédés Biologiques, Génie Enzymatique et Microbien (ProBioGem), Université de Lille, Lille, France

2019-2021: Research & Development Engineer in Enzymatic Processes
SAS GECCO, Institut Charles VIOLLETTE – Laboratoire des Procédés Biologiques, Génie Enzymatique et Microbien (ProBioGem), Université de Lille, Lille, France

2016-2018: Postdoctoral Fellow in Biocatalysis – Bioprocesses
Institut Charles VIOLLETTE – Laboratoire des Procédés Biologiques, Génie Enzymatique et Microbien (ProBioGem), Université de Lille, Lille, France

2015-2016: Postdoctoral Fellow in Biochemistry – Toxicology
Institut de Chimie Moléculaire (ICMUB-UMR-CNRS6302), Université de Bourgogne, Dijon, France
Laboratoire de Nutrition et Toxicologie (NuTox), INSERM -UMR U866-Agrosup, Dijon, France

2013-2015: Temporary Teaching and Research Attaché (ATER) in Biochemistry – Food Biotechnology
École nationale supérieure d’agronomie et des industries alimentaires (ENSAIA), Université de Lorraine, Nancy, France

2009-2013: Ph.D. Researcher in Biotechnology and Food Processes
Laboratoire d’Ingénierie des Biomolécules (LIBio), Laboratoire Réactions et Génie des procédés (LRGP)-ENSAIA, Université de Lorraine, Nancy, France

📚 Supervision and Collective Responsibilities

  • Supervised several Master’s and Ph.D. students in various projects related to enzymatic purification, functionalization, and biotests development.
  • Managed projects on the valorization of food waste and biodiesel by-products, emphasizing circular economy principles.

🧬 Skills and Expertise

  • Circular Economy: Valorization of food waste and biomass, biodiesel production, energy recovery.
  • Biosynthesis/Biocatalysis: Enzyme purification and characterization, oxidative processes, esterification, transesterification, kinetic studies, various enzymes like lipase, polyphenol oxidases, cellulase, amidase, and decarboxylase.
  • Structural Characterization: UV-Vis spectroscopy, HPLC, LC-MS, GC-MS, FT-IR, NMR.
  • Industrial Processes: Extraction, purification, separation, sterilization, pasteurization, atomization, evaporation, lyophilization.
  • Physicochemical Properties: Particle size, color parameters, viscosity, thickness, zeta potential, melting and boiling points, colloidal stability, water sorption isotherms, thermal properties.
  • Biochemistry: Antioxidant tests, microbiological assays, cell culture, cytotoxicity, genotoxicity, biocompatibility, polymer chemistry, food analysis.
  • Technical Skills: Expertise with various analytical instruments and techniques, including FT-IR, NMR, HPLC, LC-MS, SEM, TEM, and many others.
  • Statistical Analysis: ANOVA, Duncan’s Multiple Range tests.
  • Certifications: Management, Biotechnology, Life Cycle Analysis (SimaPro).

🌐 Language and Computer Proficiency

  • Languages:
    • French (Fluent)
    • English (Fluent)
    • Arabic (Native)
  • Computer Skills:
    • Microsoft Office (Word, Excel, PowerPoint)

This summary encapsulates the academic and professional journey of Abdulhadi ALJAWISH, emphasizing his vast experience in biotechnological processes, food science, and enzymatic applications.

 

📊🔬Notable Publication:

 

  • Bioprocesses for the Biodiesel Production from Waste Oils and Valorization of Glycerol
    • Authors: Decarpigny, C., Aljawish, A., His, C., Millares, M., Froidevaux, R.
    • Journal: Energies
    • Year: 2022

 

  • Green synthesis of glyco-phenol by enzymatic coupling between ferulic acid and glucosamine: An ecofriendly procedure
    • Authors: Aljawish, A., Chevalot, I., Paris, C., Muniglia, L.
    • Journal: Biotechnology and Applied Biochemistry
    • Year: 2022

 

  • Enzymatic Oxidation of Ferulic Acid as a Way of Preparing New Derivatives
    • Authors: Aljawish, A., Chevalot, I., Paris, C., Muniglia, L.
    • Journal: BioTech
    • Year: 2022

 

  • Comparing the efficiency of extracting antioxidant polyphenols from spent coffee grounds using an innovative ultrasound-assisted extraction equipment versus conventional method
    • Authors: Beaudor, M., Vauchel, P., Pradal, D., Aljawish, A., Phalip, V.
    • Journal: Chemical Engineering and Processing – Process Intensification
    • Year: 2023

 

  • Synthesis and characterization of release agent from used cooking oil at the concrete/formwork interface
    • Authors: Libessart, L., Anceur, R., Djelal, C., Aljawish, A., Millares, M.
    • Journal: International Journal of Environmental Science and Technology
    • Year: 2023

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Published on by Oncology

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • Zitate           4439
  • h-index        35
  • i10-index     49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION:

Citation: 08         Year: 2022

Citation: 01        Year: 2023